endocrine therapy in postmenopausal women with ER + breast cancer. These studies have generally compared the rates of objective response and breast-conserving surgery among treatment with tamoxifen, anastrozole, anastrozole plus tamoxifen, and letrozole
Search Results
Breast Cancer Version 3.2014
William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar
Breast Cancer
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff
Gail MH Costantino JP Bryant J . Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer . J Natl Cancer Inst 1999 ; 91 : 1829 – 1846 . 4 Dupont WD Page DL . Risk factors for breast cancer in women with
Caring for Breast Cancer Survivors
Harold J. Burstein
end-of-the-year clinics. The results of the ATLAS study were presented at San Antonio. This study addressed the question of extended course tamoxifen treatment beyond 5 years. The data suggest that longer durations of endocrine therapy with tamoxifen
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead
.57–0.94; P =.01). 32 In a multivariate analysis that took into account factors associated with lower IBTR, including grade, ER-positive status, use of adjuvant tamoxifen, margin status, and age, the benefit of RT boost still remained statistically
Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis
Erwei Zeng, Wei He, Karin E. Smedby, and Kamila Czene
), including tamoxifen and/or aromatase inhibitors (AIs), have been proven to reduce breast cancer mortality by approximately 30% for tamoxifen and 40% for AIs for estrogen receptor–positive patients in randomized clinical trials. 4 – 6 However, despite the
Breast Cancer, Version 1.2016
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, and Rashmi Kumar
(AI; with ovarian suppression for premenopausal women) or tamoxifen. The preferred endocrine therapy option for postmenopausal women is an AI. HER2-Targeted Therapy: For patients with HER2-positive breast cancer who are candidates for preoperative
Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials
David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman
Castiglione-Gertsch M . Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group trial VII . J Clin Oncol 2000 ; 18 : 1412 – 1422
Invasive Breast Cancer
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars
randomized to undergo lumpectomy with whole breast radiation or lumpectomy alone, both with tamoxifen for 5 years. Locoregional recurrence rates were 1% in the lumpectomy, radiation, and tamoxifen arm, and 4% in the lumpectomy plus tamoxifen arm. No
Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy
Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer
of treatment and not a preexisting problem or from another cause. The National Surgical Adjuvant Breast and Bowel Project (NSABP) developed the Symptom Measurement tool to assess the toxicity of chemopreventive tamoxifen in women enrolled in
Use of Biomarkers and Multigene Assays in Breast Cancer
Lee S. Schwartzberg
impactful way we can use these tests,” Dr. Schwartzberg remarked. In NSABP B-14, the benefit of tamoxifen (vs placebo) in patients with ER-positive cancer was seen in the low and intermediate RS groups, but not the high RS group. Discrimination by RS
